Shots:
- Otsuka Pharmaceutical has entered into an agreement with Cantargia for the acquisition of all assets related to its P-I IL-1RAP antagonist program, CAN10
- Otsuka Pharmaceutical will handle global development, regulatory approvals, manufacturing, & commercialization of CAN10. Otsuka has also acquired 3G5 as a backup antibody & holds exclusive negotiation right for next-gen IL-1RAP antibodies for 2yrs.
- As per the deal, Cantargia will receive $33M upfront & ~$580M in development, regulatory as well as commercial milestones, with up to double digits tiered earn-out payments on global sales; closing is expected in Q3’25
Ref: Cantargia | Image: Cantargia & Otsuka Pharmaceutical| Press Release
Related News:- Bayer Reports the US FDA’s Approval of Kerendia (Finerenone) to Treat Heart Failure (HF)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
